ArticleInvestigational new drugs2012

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Pamela L Kunz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.